

Evonik polyamide PA1010 quality confirmed through FDA approval

November 7, 2014

Evonik Industries has received a food contact substance notification (FCN) for its family of PA1010 polyamides. The VESTAMID® Terra DS16 natural may be used as a basic polymer in the production of articles intended for food contact. Details to the approved applications can be found in the FCN#001439. Whereby, essentially, it may be come in contact with all types of food at chilled to elevated room temperatures for single use as well all types of food in repeated use application up to 100°C.

Thomas Lange

Contact specialized press

High Performance Polymers

Phone +49 2365-49-9227

thomas.lange2@evonik.com

Approval is based on the simulation and actual tested migration behavior of the monomers, oligomers and other trace substances. Much like the previous approvals set by the EU (Regulation-EC #1935/2004) for the monomer DMDA (CAS646-25-3) very low specific migration levels (SML) are required.

Such expertise and dedication to superior quality has enabled the resulting SML's to be well within the limits for food contact applications. "Receiving the FDA approval is a validation that our efforts to strive for the best quality bio-based polyamides on the market has paid off", said Dr. Benjamin Brehmer, Business Manager for biopolymers. "This milestone also allows us to confidently enter new markets with clarity of the regulatory situation".

VESTAMID® Terra DS is based on polyamide 1010, which is the polycondensation product of 1,10-decamethylene diamine (D) and 1,10-decanedioic diacid (sebacic acid - S). Both decamethylene diamine and sebacic acid are derived from castor oil, making Terra DS a 100% bio-content polymer. VESTAMID® Terra HS is based on polyamide 610, which is the polycondensation product of 1,6-hexamethylene diamine (H) and 1,10-decanedioic diacid (sebacic acid - S). VESTAMID® Terra HS is a 63% bio-content polymer. PA610 has already received both EU and USA food contact approvals with non-alcoholic foods. Having food contact approvals for both products enables Evonik to offer a broader portfolio of bio-based polyamide to the market.

VESTAMID® Terra is derived partly or entirely from the castor bean plant, a raw material that is not animal feed, and which does not compete with that of food crops. Unlike other bio-sourced products, biopolyamide VESTAMID® Terra is a high performance polymer, so there are no

Evonik Industries AG

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

www.vestamid.com

Chairman of the Supervisory Board

Dr. Werner Müller

Executive Board

Dr. Klaus Engel, Chairman

Christian Kullmann

Thomas Wessel

Patrik Wohlhauser

Dr. Uwe Wolf

Registered Office: Essen

Register Court: Essen Local Court

Commercial Registry B 19474

VAT ID no. DE 811160003

restrictions on its service life and it retains impressive physical and chemical resistance properties similar to petroleum-based high performance polymers.



Image Caption

Castor beans are the basis of the biobased polyamide VESTAMID® Terra

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.